LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free earnings report on Novartis AG (NYSE: NVS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=NVS. The Company reported its second quarter fiscal 2018 operating and financial results on July 18, 2018. The drug-maker outperformed top- and bottom-line expectations. Register today and get access to over 1,000 Free Research Reports by joining our site below:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Novartis most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Earnings Highlights and Summary
For the second quarter of the fiscal year 2018, Novartis’ net sales were $13.2 billion, up 7% compared to $12.2 billion in Q2 2017, driven by volume growth, mainly in Innovative Medicines. The Company’s revenue numbers beat analysts’ estimates by $220 million.
During Q2 2018, Novartis reported an operating income of $2.5 billion, up 9% compared to $2.3 billion in Q2 2017, primarily driven by higher sales and an improved gross margin. The Company’s core operating income was $3.5 billion in the reported quarter, up 9% on a y-o-y basis, driven by higher sales and an improved gross margin.
For Q2 2018, Novartis posted a net income of $7.8 billion, or $3.34 per share, compared to $2.0 billion, or $0.84 per share, in Q2 2017, with the results for the reported quarter benefiting from a $5.7 billion net gain recognized from the sale of its stake in the GSK consumer healthcare joint venture.
Novartis’ core net income was $3.0 billion, or $1.29 per diluted share, in Q2 2018 compared to $2.9 billion, or $1.22 per diluted share in Q2 2017. The Company’s earnings numbers beat Wall Street’s estimates of $1.27 per share.
During Q2 2018, Novartis’ Innovative Medicines segment’s net sales jumped 10% to $8.9 billion on a y-o-y basis. The segment’s volume contributed 12% to sales growth, while generic competition had a negative impact of 3%, primarily due to Gleevec/Glivec in the US and Europe and certain Ophthalmology products. The segment’s operating income advanced 11% to $2.3 billion on a y-o-y basis in Q2 2018, mainly driven by higher sales and an improved gross margin. The segment’s core operating income was $2.9 billion, up 14% on a y-o-y basis.
For Q2 2018, Novartis’ Sandoz segment’s net sales remained flat at $2.5 billion on a y-o-y basis, as a price erosion of 9%, mainly in the US, was largely offset by a volume growth of 7%. Excluding the US, the segment’s net sales grew by 5% on a y-o-y basis. During the reported quarter, the Sandoz segment’s operating income was $328 million, primarily due to lower sales and higher ex-US M&S investments, partly offset by a legal settlement gain. The segment’s core operating income was $480 million in Q2 2018, down 3% on a y-o-y basis.
Novartis’ Alcon segment’s net sales were $1.8 billion in Q2 2018, up 7% on a y-o-y basis. The Alcon segment’s results reflected the sixth consecutive quarter of net sales growth as a result of improved operations, innovation, and customer relationships. The segment’s operating income was $65 million in the reported quarter compared to $29 million in the prior year’s same quarter, mainly driven by higher sales and an improved gross margin. The segment’s core operating income was $338 million, up 16% on a y-o-y basis.
Novartis’ free cash flow amounted to $3.6 billion in Q2 2018, up 10% compared to $3.2 billion in Q2 2017, driven by higher cash flows from operating activities. During H1 2018, the Company repurchased 9.2 million shares for $0.7 billion to mitigate dilution related to participation plans of associates. On June 29, 2018, Novartis announced a new up-to $5 billion share buyback to be executed by the end of 2019 on the second trading line.
As of June 30, 2018, the Company’s net debt increased by $0.2 billion to $19.2 billion versus December 31, 2017; mainly driven by the annual dividend payment of $7.0 billion, the acquisition of Advanced Accelerator Applications S.A. in Q1 2018 and of AveXis, Inc. in Q2 2018, and mostly offset by the inflow from the sale of the stake in the GSK consumer healthcare joint venture and $5.5 billion free cash flow in H1 2018.
For FY18, Novartis is forecasting group net sales to grow in the low- to mid-single digit. The Company’s group core operating income is expected to grow in the mid- to high-single digit for FY18.
Stock Performance Snapshot
July 19, 2018 - At Thursday’s closing bell, Novartis’ stock slightly fell 0.20%, ending the trading session at $80.80.
Volume traded for the day: 3.76 million shares, which was above the 3-month average volume of 1.76 million shares.
Stock performance in the last month – up 9.83%; and previous three-month period – up 2.28%
After yesterday’s close, Novartis’ market cap was at $199.29 billion.
Price to Earnings (P/E) ratio was at 23.83.
The stock has a dividend yield of 3.69%.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia